REQUEST A DEMO
Total
USD $0.00
Search more companies

Otisifarm AO (Russia)

Main Activities: Pharmaceutical and Medicine Manufacturing | Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Otisifarm AO Profile Updated: August 18, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Russian Download a sample report

Отисифарм ПАО is one of the largest companies in the Russian pharmaceutical market of OTC drugs on the representation of drugs in major therapeutic categories. The company was formed as a result of allocation of OTC business in the process of reorganization of the Russian pharmaceutical company Pharmstandard in late 2013. Portfolio OTISIFARM presented by such well-known and popular brands as Arbidol, Amixin®, Afobazol®, NOOPEPT®, ATSIPOL®, LAKTAZAR®, Codelac®, MAKSIKOLD®, RINOSTOP®, Complivit®, SELMEVIT®, MAGNELIS® B6 LAKTONORM®, NEKST®, Pentalgin®, Flucostat®, TSIKLOVITA®, TSINOKAP® and others.

Headquarters
Testovskaya, 10, 12 Pom II Kom 29
Moscow; Moscow; Postal Code: 123112

Contact Details: Purchase the Otisifarm AO report to view the information.

Website: http://flukostat.ru

Basic Information
Total Employees:
Purchase the Otisifarm AO report to view the information.
Outstanding Shares:
Purchase the Otisifarm AO report to view the information.
Registered Capital:
Purchase the Otisifarm AO report to view the information.
Financial Auditors:
Purchase the Otisifarm AO report to view the information.
Incorporation Date:
February 01, 2024
Key Executives
Purchase this report to view the information.
General Director
Ownership Details
Purchase this report to view the information.
82.25%
Purchase this report to view the information.
17.75%
Subsidiaries
Otisifarm Pro AO
100%
Company Performance
Financial values in the chart are available after Otisifarm AO report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RUB. Absolute financial data is included in the purchased report.
Net sales revenue
-22.41%
Total operating revenue
-22.41%
Operating profit (EBIT)
-32.83%
Net Profit (Loss) for the Period
-66.7%
Total assets
-52%
Total equity
-59.28%
Operating Profit Margin (ROS)
-7.7%
Net Profit Margin
-28.72%
Return on Equity (ROE)
-4.13%
Quick Ratio
-12.68%
Cash Ratio
-6.6%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?